A dual role for the N-terminal domain of the IL-3 receptor in cell signalling
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A dual role for the N-terminal domain of the IL-3 receptor in cell signalling
Authors
Keywords
-
Journal
Nature Communications
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-22
DOI
10.1038/s41467-017-02633-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dynamic Modulation of Binding Affinity as a Mechanism for Regulating Interferon Signaling
- (2017) Hongchun Li et al. JOURNAL OF MOLECULAR BIOLOGY
- Adaptive evolution of interleukin-3 (IL3), a gene associated with brain volume variation in general human populations
- (2016) Ming Li et al. HUMAN GENETICS
- Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling
- (2016) Sophie E. Broughton et al. STRUCTURE
- MDTraj: A Modern Open Library for the Analysis of Molecular Dynamics Trajectories
- (2015) Robert T. McGibbon et al. BIOPHYSICAL JOURNAL
- Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
- (2015) M. Al-Hussaini et al. BLOOD
- HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia
- (2015) Gabriela Brumatti et al. Oncotarget
- Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
- (2014) A. E. Frankel et al. BLOOD
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
- (2014) Olga Frolova et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
- (2014) F. Angelot-Delettre et al. HAEMATOLOGICA
- Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
- (2014) S J Busfield et al. LEUKEMIA
- Dual Mechanism of Interleukin-3 Receptor Blockade by an Anti-Cancer Antibody
- (2014) Sophie E. Broughton et al. Cell Reports
- Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362
- (2014) Sophie E. Broughton et al. Acta Crystallographica Section F-Structural Biology Communications
- Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells
- (2013) E. Nievergall et al. BLOOD
- Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
- (2013) Sarah Tettamanti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Signalling by the βc family of cytokines
- (2013) Timothy R. Hercus et al. CYTOKINE & GROWTH FACTOR REVIEWS
- High Yield Production of a Soluble Human Interleukin-3 Variant from E. coli with Wild-Type Bioactivity and Improved Radiolabeling Properties
- (2013) Timothy R. Hercus et al. PLoS One
- The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling
- (2012) Sophie E. Broughton et al. IMMUNOLOGICAL REVIEWS
- Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone ϕ, ψ and Side-Chain χ1 and χ2 Dihedral Angles
- (2012) Robert B. Best et al. Journal of Chemical Theory and Computation
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- The Interleukin 3 Gene (IL3) Contributes to Human Brain Volume Variation by Regulating Proliferation and Survival of Neural Progenitors
- (2012) Xiong-jian Luo et al. PLoS One
- Structural basis of interleukin-5 dimer recognition by its α receptor
- (2012) Seisuke Kusano et al. PROTEIN SCIENCE
- REFMAC5 for the refinement of macromolecular crystal structures
- (2011) Garib N. Murshudov et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons
- (2011) Christoph Thomas et al. CELL
- High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
- (2011) F. Vergez et al. HAEMATOLOGICA
- IL-3 is a novel target to interfere with tumor vasculature
- (2011) P Dentelli et al. ONCOGENE
- Structure Analysis of the IL-5 Ligand-Receptor Complex Reveals a Wrench-like Architecture for IL-5Rα
- (2011) Edwin Patino et al. STRUCTURE
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Molecular Basis for Shared Cytokine Recognition Revealed in the Structure of an Unusually High Affinity Complex between IL-13 and IL-13Rα2
- (2010) Patrick J. Lupardus et al. STRUCTURE
- Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
- (2009) Liqing Jin et al. Cell Stem Cell
- The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation
- (2008) Guido Hansen et al. CELL
- Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System
- (2008) Sherry L. LaPorte et al. CELL
- A New Isoform of Interleukin-3 Receptor α with Novel Differentiation Activity and High Affinity Binding Mode
- (2008) Jinglong Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
- (2008) Arthur Frankel et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More